New York, NY -- (SBWIRE) -- 12/27/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Chelsea Therapeutics International Ltd (NASDAQ:CHTP), Mast Therapeutics Inc (NYSEMKT:MSTX), Capstone Turbine Corporation (NASDAQ:CPST), Enzon Pharmaceuticals Inc (NASDAQ:ENZN)
Chelsea Therapeutics International Ltd (NASDAQ:CHTP) showed a volume of 1.37 million shares by the end of last trade whereas the average volume of the stock remained 1.69 million shares. The stock opened the session at $4.50 but then moved to $4.41. At that price, the stock showed a negative performance of -0.90%. Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), associated with primary autonomic failure and falls related to NOH in Parkinson’s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension (IDH), fibromyalgia, adult attention deficit hyperactivity disorder (ADHD),
Will CHTP Get Buyers Even After The Recent Rally? Find Out Here
Mast Therapeutics Inc (NYSEMKT:MSTX) opened the session at $0.44 and closed the session at $0.446. The stock showed a positive performance of 2.51% in previous trading session. Traded with volume of 1.37 million shares in the prior session and the average volume of the stock remained 1.14 million shares. Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. As of December 31, 2011,
For How Long MSTX will fight for Profitability? Read This Trend Analysis report
Capstone Turbine Corporation (NASDAQ:CPST) opened the session at $1.25 and closed the session at $1.22. The stock showed a negative performance of -3.17% in previous trading session. Traded with volume of 1.31million shares in the prior session and the average volume of the stock remained 2.08 million shares. The beta of the stock remained 1.96. Capstone Turbine Corporation (Capstone) develops, manufactures, markets and services microturbine technology solutions for use in stationary distributed power generation applications, including cogeneration (combined heat and power (CHP), integrated combined heat and power (ICHP), and combined cooling, heat and power (CCHP)), renewable energy, natural resources and critical power supply. In addition, its microturbines can be used as battery charging generators for hybrid electric vehicle applications.
Why Should Investors Buy CPST After the Recent Fall? Just Go Here and Find Out
Enzon Pharmaceuticals Inc (NASDAQ:ENZN) the stock advanced 1.74% and finished the session at $1.17. Traded with volume of 1.31 million shares in the prior session and the average volume of the stock remained 423,317.00 shares. The beta of the stock remained 0.83. Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company’s drug development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology) and third-generation messenger ribonucleic acid (mRNA) antagonists utilizing the Locked Nucleic Acid (LNA) technology. The Company has four compounds in human clinical development, a PEGylated version of the active metabolite of the cancer drug, irinotecan, PEG-SN38,
Will ENZN Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)